Gastroenterology Department, Instituto Português de Oncologia de Lisboa, Portugal.
United European Gastroenterol J. 2016 Jun;4(3):395-402. doi: 10.1177/2050640615612934. Epub 2015 Oct 30.
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is closely associated with Helicobacter pylori (HP) infection. Our aim was to evaluate demographic, clinical and endoscopic characteristics of gastric MALT lymphoma patients, as well as to analyse response to treatment and factors that affect complete remission (CR) and relapse. We also assessed the long-term prognosis.
The study involved a retrospective evaluation of consecutive patients admitted with gastric MALT lymphoma (1993-2013).
A total of 144 patients (76 men; mean age 56) were included. At stage EI, 94/103 patients (92%) received HP eradication and 78 (83%) achieved CR after a mean period of 7 months (2-63 months) and 67 (86%) remained in CR after a mean follow-up time of 105 months. HP infection status (p = 0.004) and lymphoma localisation to the antrum plus body (p = 0.016) were associated with higher and lower CR rates, respectively. Relapse occurred in 11/78 (14%) patients after a mean period of 21 months. The absence of HP re-infection (p = 0.038), the need of only one eradication regimen (p = 0.009) and antrum lymphomas (p = 0.031) correlated with lower relapse rates. At stage EII, HP eradication was performed in 17/24 patients but only five experienced CR (30%). Among 16 patients diagnosed at stage EIV, nine achieved CR after chemotherapy ± surgery and 3/7 without remission died due to disease progression. The 5- and 10-year overall disease free survival rates were 90.5% and 79.1%, respectively.
Most patients were diagnosed at an early stage. Eradication therapy was highly effective in inducing complete remission. Long-term evaluation showed that the long-term prognosis was very favourable.
胃黏膜相关淋巴组织(MALT)淋巴瘤与幽门螺杆菌(HP)感染密切相关。我们的目的是评估胃 MALT 淋巴瘤患者的人口统计学、临床和内镜特征,分析对治疗的反应以及影响完全缓解(CR)和复发的因素。我们还评估了长期预后。
这项研究回顾性评估了 1993 年至 2013 年间连续收治的胃 MALT 淋巴瘤患者。
共纳入 144 例患者(76 例男性;平均年龄 56 岁)。在 E1 期,103 例患者中有 94 例(92%)接受了 HP 根除治疗,78 例(83%)在平均 7 个月(2-63 个月)后获得 CR,67 例(86%)在平均 105 个月的随访后仍处于 CR 状态。HP 感染状态(p=0.004)和淋巴瘤位于胃窦和体部(p=0.016)与更高和更低的 CR 率相关。78 例获得 CR 的患者中有 11 例(14%)在平均 21 个月后复发。没有 HP 再感染(p=0.038)、仅需要一种根除方案(p=0.009)和胃窦部淋巴瘤(p=0.031)与较低的复发率相关。在 E2 期,24 例患者中有 17 例接受了 HP 根除治疗,但只有 5 例获得 CR(30%)。在 E3 期诊断的 16 例患者中,9 例经化疗联合手术获得 CR,7 例无缓解患者因疾病进展死亡。5 年和 10 年无病生存率分别为 90.5%和 79.1%。
大多数患者在早期阶段被诊断。根除治疗在诱导完全缓解方面非常有效。长期评估显示,长期预后非常良好。